WASHINGTON, Jan 22 (Reuters) - Optimer Pharmaceuticals Inc., a development stage company, on Monday said it is planning 5.25 million share in an initial public offering for $12 to $14 per share.
WASHINGTON, Jan 22 (Reuters) - Optimer Pharmaceuticals Inc., a development stage company, on Monday said it is planning 5.25 million share in an initial public offering for $12 to $14 per share.